Liquidia Corporation
MUN:LT4 株式レポート
Liquidia マネジメント Liquidiaの CEO はRoger Jeffsで、 Jan2022年に任命され、 の在任期間は 2.83年です。 の年間総報酬は$ 4.89Mで、 14.1%給与と85.9%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の2.39%を直接所有しており、その価値は€ 20.37M 。経営陣と取締役会の平均在任期間はそれぞれ3.3年と5.1年です。
主要情報 CEO給与比率 14.1% CEO在任期間 2.8yrs CEOの所有権 2.4% 経営陣の平均在職期間 3.3yrs 取締役会の平均在任期間 5.1yrs
経営陣の近況
Insufficient new directors Oct 03
Insufficient new directors Aug 28
Liquidia Corporation, Annual General Meeting, Jun 20, 2024 May 01
CEO & Director recently sold €416k worth of stock Mar 21
Insufficient new directors Mar 07
Insufficient new directors Jan 25
すべての更新を表示
Liquidia Corporation to Report Q3, 2024 Results on Nov 13, 2024 Nov 06
Liquidia Corporation to Report Q3, 2024 Results on Nov 11, 2024 Nov 04
Insufficient new directors Oct 03
Liquidia Corporation Announces Poster Presentation and Medical Theater at the CHEST 2024 Annual Meeting Oct 01 Liquidia Corporation has completed a Follow-on Equity Offering in the amount of $57.499999 million. Liquidia Corporation has completed a Follow-on Equity Offering in the amount of $57.499999 million. Sep 11
No longer forecast to breakeven Aug 28
Insufficient new directors Aug 28
Liquidia Corporation Files Litigation to Challenge Regulatory Exclusivity Blocking Access to Yutrepia (Treprostinil) Inhalation Powder for Patients Suffering with PAH and PH-ILD Aug 22
Liquidia Corporation Announces U.S. Food and Drug Administration Grants Tentative Approval of YUTPIA®? (Treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) Aug 19
Liquidia Corporation to Report Q2, 2024 Results on Aug 07, 2024 Jul 31
District Court Issues Favorable Ruling and Denies United Therapeutics’ Request to Block YUTREPIA™ Launch Jun 05
First quarter 2024 earnings released: US$0.54 loss per share (vs US$0.18 loss in 1Q 2023) May 15
New minor risk - Profitability May 14
No longer forecast to breakeven May 14
Liquidia Corporation to Report Q1, 2024 Results on May 14, 2024 May 09
Liquidia Corporation, Annual General Meeting, Jun 20, 2024 May 01
Liquidia Corporation Provides Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA Approval of YUTREPIA™ (treprostinil) Inhalation Powder Apr 02
CEO & Director recently sold €416k worth of stock Mar 21
Full year 2023 earnings released: US$1.21 loss per share (vs US$0.67 loss in FY 2022) Mar 14
Insufficient new directors Mar 07
Liquidia Corporation to Report Fiscal Year 2023 Results on Mar 13, 2024 Mar 07
Insufficient new directors Jan 25
Liquidia Corporation Provides Update on New Drug Application for YUTREPIA (Treprostinil) Inhalation Powder Jan 25
Liquidia Corporation Announces the Launch of Yutrepiatm (Treprostinil) Inhalation Powder Jan 20
Liquidia Corporation Announces Updates to Operations Leadership Jan 19 Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims Liquidia Corporation announced that it expects to receive $74.999999 million in funding from Legend Aggregator, LP Liquidia Corporation announced that it expects to receive $74.999999 million in funding from Legend Aggregator, LP Jan 05
Insufficient new directors Jan 02
Forecast to breakeven in 2026 Dec 31
Independent Director recently bought €1.8m worth of stock Dec 22 Liquidia Corporation has completed a Follow-on Equity Offering in the amount of $24.999999 million. Liquidia Corporation has filed a Follow-on Equity Offering in the amount of $24.999999 million.
Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.14 loss in 3Q 2022) Nov 11
Liquidia Corporation to Report Q3, 2023 Results on Nov 07, 2023 Nov 01
FDA Accepts Liquidia Corporation's Submission to Add PH-ILD to YUTREPIA™ Label Sep 26
United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent Office Sep 08
Liquidia Corporation to Report Q2, 2023 Results on Aug 10, 2023 Aug 04
Liquidia Corporation Submits Amendment to Add Ph-Ild Indication to Tentatively Approved Nda for Yutpia (Treprostinil) Inhalation Powder Jul 28
Liquidia Corporation Announces U.S. Federal Circuit Affirms All District Court Rulings in Patent Litigation Jul 25
Liquidia Corporation to Report Q3, 2022 Results on Nov 08, 2022 Nov 02
CEO & Director recently bought €246k worth of stock Sep 09 Liquidia Corporation Provides Update on Hatch-Waxman Litigation
High number of new directors Aug 30
CEO報酬分析 Liquidia の収益と比較して、Roger Jeffs の報酬はどのように変化したか？ 日付 総報酬 給与 会社業績 Jun 30 2024 n/a n/a -US$112m
Mar 31 2024 n/a n/a -US$108m
Dec 31 2023 US$5m US$689k -US$79m
Sep 30 2023 n/a n/a -US$58m
Jun 30 2023 n/a n/a -US$51m
Mar 31 2023 n/a n/a -US$37m
Dec 31 2022 US$11m US$325k -US$41m
Sep 30 2022 n/a n/a -US$46m
Jun 30 2022 n/a n/a -US$44m
Mar 31 2022 n/a n/a -US$41m
Dec 31 2021 US$93k n/a -US$35m
Sep 30 2021 n/a n/a -US$39m
Jun 30 2021 n/a n/a -US$47m
Mar 31 2021 n/a n/a -US$54m
Dec 31 2020 US$89k n/a -US$60m
報酬と市場: Rogerの 総報酬 ($USD 4.89M ) は、 German市場 ($USD 1.40M ) の同規模の企業の平均を上回っています。
報酬と収益: Rogerの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者 Dr. Roger A. Jeffs, Ph D., serves as Director at Liquidia Corporation (formerly known as Liquidia Technologies, Inc.) since November 2020 and serves as its Chief Executive Officer from January 3, 2022. He ... Show more
リーダーシップ・チーム 名称 ポジション 在職期間 報酬 所有権 CEO & Director 2.8yrs US$4.89m 2.39% € 20.4m COO & CFO 4yrs US$2.43m 0.12% € 987.2k General Counsel & Corporate Secretary 3.7yrs US$2.06m 0.39% € 3.4m Co-Founder 20.8yrs データなし データなし Co-Founder 20.8yrs データなし データなし Vice President of People & Culture 1.4yrs データなし データなし Chief Business Officer 1.3yrs データなし 0.073% € 619.8k Chief Commercial Officer 4yrs データなし 0.067% € 567.9k Chief Medical Officer 2.3yrs データなし 0.099% € 847.7k Senior Vice President of Manufacturing Operations less than a year データなし データなし
もっと見る
経験豊富な経営陣: LT4の経営陣は 経験豊富 であると考えられます ( 3.3年の平均在職年数)。
取締役 名称 ポジション 在職期間 報酬 所有権 CEO & Director 4yrs US$4.89m 2.39% € 20.4m Independent Director 8.2yrs US$186.91k 0.038% € 323.3k Independent Director 5.2yrs US$176.91k 0% € 0 Board Observer no data データなし データなし Board Observer no data データなし データなし Board Observer no data データなし データなし Independent Chairman 15.3yrs US$211.91k 0% € 0 Independent Director 4.8yrs US$170.66k 7.28% € 62.1m Independent Director 3.6yrs US$174.41k 0% € 0 Director 3.9yrs US$166.91k 0.057% € 482.1k Independent Director 6.8yrs US$178.16k 0% € 0 Independent Director 5.1yrs US$175.66k 0% € 0
もっと見る
経験豊富なボード: LT4の 取締役会 は 経験豊富 であると考えられます ( 5.1年の平均在任期間)。
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}